Exam (elaborations)
NR566 Week 1 Study Outline Chapter 21: Drugs Affecting the Endocrine System
- Course
- Institution
NR566 Week 1 Study Outline Chapter 21: Drugs Affecting the Endocrine System
[Show more]
Seller
Follow
instructor
Reviews received
Content preview
NR566 Week 1 Study OutlineChapter 21: Drugs Affecting the Endocrine System
Bisphosphonates
• Drugs: etidronate (Didronel), pamidronate (Aredia), risedronate (Actonel) alendronate (Fosamax),
tiludronate (Skelid), zoledronic acid (Zometa), ibandronate (Boniva)
• Used for bone support, most commonly used
• Pharmacodynamics
▪ Adhere to bone, inhibit osteoclastic activity, potent inhibitors of both normal and abnormal
bone resorption
o Etidronate (Didronel): reduces both bone resorption and bone formation because formation is
coupled with resorption
o Pamidronate (Aredia) (available as IV only)
o and risedronate (Actonel): inhibit bone resorption with out inhibiting bone formation and
mineralization
o Alendronate (Fosamax): highly selective inhibitor of bone resorption 1
▪ 100 to 500 time more potent than the other drugs
▪ Does not interfere with osteoclastic recruitment or attachment but does inhibit osteoclastic
activity
o Tiludronate (Skelid): inhibits protein-tyrosine-phosphatease, results in detachment of osteoclasts
from the bone surface
▪ Inhibits the osteoclastic proton pump
o Zoledronic acid (Zometa): inhibits osteoclastic activity and induces osteoclast apoptosis
▪ Also inhibits the increased osteoclastic activity and skeletal calcium release induced by
various stimulatory factors release by tumors
▪ Only available as IV formulation
o Ibandronate (Boniva): inhibits osteoclast activity and reduces bone resorption and turnover based
on its affinity for hydroxyapatite (part of the bone matrix)
• All drugs in this class reduce vertebral fracture however,
o Only alendronate, risedronate, and zoledronic acid have demonstrated nonvertebral fracture
reduction
o Pamidronate and zoledronic acid: only for parenteral use
• Pharmacotherapeutics
o Contraindication: uncorrected hypocalcemia, documented Barrett’s esophagus, and renal
insufficiency
o Caution: patient with GI disorders
o R/F severe esophageal adverse reactions is greater in patients who lie down after taking these drugs
or fail to take with a full glass of water
o Etidronate has been withheld from patients with enterocolitis r/t diarrhea particularly at high doses
▪ Associated with fracture in patients with Paget’s disease when given high doses or when
therapy lasted longer than 6 months
• Monitor with x-rays and lab work to assess for lesions
• Rare femur fracture in non-Paget’s patients using bisphosphonates
o IV formulations associated with higher renal toxicity risk especially with rapid infusion
▪ Check crt prior to every dose is required, force fluids before and after infusion
,• Clinical Use (Page 546 Dosing Chart)
o Osteoporosis
▪ Prevention and treatment of osteoporosis and its risk for fracture in men and postmenopausal
women (especially vertebral fractures)
▪ First line drugs: Alendronate, risedronate, and zolendronic acid with hip fracture reductions,
FDA approved for this indication
▪ Second-line drug: Ibandronate
▪ Ibandronate and zoledronic acid come in IV form
▪ Alendronate PO solution (Binosto) and PO tablets
▪ Zoledronic acid: only alternative form that shows evidence of hip fracture reduction
▪ Prophylactic use in patients with early osteopenia r/t long term use of medications that
contribute to bone loss
• Includes (thyroid hormone, aromatase inhibitors, and glucocorticoids, PPIs, SSRIs)
▪ It is recommended that all adults taking more than 7.5 mg of prednisone or its equivalent for
more than 3 weeks be given alendronate or risedrone
▪ In very high risk patients, maximum 2-year use of teriparatide (Forteo) (bone mass benefit
disappears after d/c) a parathyroid hormone, may be more efficacious
• Bisphosphonates: bone mass benefit does not decline for 5 years
▪ Alendronate and risedronate initial doses for prevention of bone loss: 5mg/day or 35mg/week
▪ For existing osteoporosis: alendronate 10mg/day or 70mg/week
▪ Risedronate: 75mg for 2 days or 150mg once a month
o Paget’s Disease (Osteitis Deformans)
▪ All bisphosphonates are used to treat Paget’s disease when the alkaline phosphatase is at least
twice the upper limit of normal
▪ Asymptomatic or at risk for future complications from their disease
▪ Symptomatic Paget’s best treated with etidronate
▪ Etidronate slows accelerated bone turnover in pagetic lesions and to a lesser extend in normal
bone
▪ Reduced turnover causes symptomatic improvement: less bone pain and decreased fractures
▪ 5-10 mg/kg daily for up to 6 months or 11 to 20 mg/kg daily for 3 months
▪ For all drugs indications for retreatment are evidence of active disease or failure to normalize
alkaline phosphatase levels
▪ Supplemental calcium and vitamin D if dietary intake is not adequate
▪ Space calcium supplements and bisphosphonates to prevent reduced bioavailability
o Heterotopic Ossification
▪ Complications of THR
▪ Etidronate: first line
▪ Heterotopic ossification r/t spinal cord injury
▪ Use as soon as possible after injury
• Drug Interactions
o Adverse GI reactions, interact with drugs that affect the GI tract
▪ Histamine 2 blocking agents double alendronate bioavailability but the impact with unknow
o Calcium supplements and antacids interfere with bisphosphonate absorption when taken within 1 hr
o R/F GI bleeding is increased when ASA and NSAIDs are concomitantly taken
o ASA may decrease the bioavailability of tiludronate by up to 50% when taken 2 hrs after the
tiludronate
, o Indomethacin increases the bioavailability of tiludronate by 2- to 4- fold
▪ Diclofenac does not significantly alter bioavailability therefore each NSAID must be
evaluated individually
o Concurrent use of bisphosphonates and other drugs known to build bone density (estrogens and
SERMs) have additive bone density however fracture reduction potential is unknown
• ADRs
o All bisphosphonates: musculoskeletal pain
▪ More common in Paget’s disease
▪ More common in those taking risedronate
▪ High doses of etidronate
▪ Rare reports of osteonecrosis of the jaw in active dental disease, invasive procedure,
especially in CA patients
• Can occur without dental issues in those receiving frequent high IV doses
▪ R/F A-fib
• Bioavailability of bisphosphonate drugs and appropriate patient education
o Absorption and bioavailability of oral doses are significantly reduced by the presence of food in the
gut or other preparations containing divalent cations
o To enhance absorption take with 8 oz of water, no other food or drink and remain upright for at least
half an hr (1 hour with ibandronate)
o Histamine 2 blocking agents double alendronate bioavailability but the impact with unknow
o ASA may decrease the bioavailability of tiludronate by up to 50% when taken 2 hrs after the
tiludronate
o Indomethacin increases the bioavailability of tiludronate by 2- to 4- fold
▪ Diclofenac does not significantly alter bioavailability therefore each NSAID must be
evaluated individually
o Patient education: Take oral drugs first thing in the morning at least 30 minutes prior to other
medications, beverages, or food (60 minutes for ibandronate)
o Etidronate and tiludronate take 2 hours before food
o Alendronate, ibandronate, risedronate, and tiludronate should be taken with 8 oz of plain water
o Mineral water, coffee, OJ, and other drinks greatly reduce absorption
o Supplemental calcium or antacids take the bisphosphonate at least 1 hr before these drugs
o Skip missed daily doses and resume the next morning
o Sit up for at least 30 mins after taking to decrease risk of esophageal irritation (1hr for ibandronate)
• Adverse effects associated with long-term use
o Etidronate: Fractures in patients with Paget’s disease when given high doses or when therapy lasted
longer than 6 months
o Oral drugs in this class: rare osteonecrosis of the jaw after 3 years of use (higher risk in IV drugs)
Growth hormones
• Drugs: somatropin (Nutropin and Nutropin AQ, Gentropin, Humatrope, Norditropin, Nutropin,
Accretropi9n, Saizen, Serostim) and somatrem (Protropin)
• Dosage of the various forms of somatropin varies by manufacturer
• Pharmacodynamics
o GHRH secreted by hypothalamus in response to decreased serum glucose
o GHRH then binds to receptors in the anterior pituitary, secrets GH (somatotropin)
o Passes through cell membrane, fosters proteins synthesis, fat breakdown, and tissue growth
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller instructor. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $10.49. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
67096 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now